Tamiflu Indication:

For the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days. Also for the prophylaxis of influenza in adult patients and adolescents 13 years and older.

Tamiflu Mechanism Of Action:

Tamiflu is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

Tamiflu Drug Interactions:

Not Available

Tamiflu Food Interactions:

Not Available

Tamiflu Generic Name:


  • Oseltamivir phosphate

Drug Type:

Small Molecule; Approved


Readily absorbed from the gastrointestinal tract after oral administration with a bioavailability of 75%.

Toxicity (Overdose):

At present, there has been no experience with overdose. Single doses of up to 1000 mg of oseltamivir have been associated with nausea and/or vomiting. Mean LD (intravenous, mouse) = 100 mg/kg.

Protein Binding:

Oseltamivir carboxylate: low (3%), Oseltamivir free base: 42%.


Extensively converted to oseltamivir carboxylate by esterases located predominantly in the liver. Neither oseltamivir nor oseltamivir carboxylate is a substrate for, or inhibitor of, cytochrome P450 isoforms. At least 75% of an oral dose reaches the systemic circulation as oseltamivir carboxylate.

Half Life:

1 to 3 hours in most subjects after oral administration.

Dosage Forms of Tamiflu:

Capsule Oral
Powder, for suspension Oral
Powder, for suspension Oral
Capsule Oral

Chemical IUPAC Name:

ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate

Organisms Affected:

Influenza Virus

Tamiflu to general, pharmacology

General, pharmacology..